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ZO-1 binds numerous transmembrane and cytoplasmic proteins and is required for assembly of both adherens and tight
junctions, but its role in defining barrier properties of an established tight junction is unknown. We depleted ZO-1 in
MDCK cells using siRNA methods and observed specific defects in the barrier for large solutes, even though flux through
the small claudin pores was unaffected. This permeability increase was accompanied by morphological alterations and
reorganization of apical actin and myosin. The permeability defect, and to a lesser extent morphological changes, could
be rescued by reexpression of either full-length ZO-1 or an N-terminal construct containing the PDZ, SH3, and GUK
domains. ZO-2 knockdown did not replicate either the permeability or morphological phenotypes seen in the ZO-1
knockdown, suggesting that ZO-1 and -2 are not functionally redundant for these functions. Wild-type and knockdown
MDCK cells had differing physiological and morphological responses to pharmacologic interventions targeting myosin
activity. Use of the ROCK inhibitor Y27632 or myosin inhibitor blebbistatin increased TER in wild-type cells, whereas
ZO-1 knockdown monolayers were either unaffected or changed in the opposite direction; paracellular flux and myosin
localization were also differentially affected. These studies are the first direct evidence that ZO-1 limits solute perme-
ability in established tight junctions, perhaps by forming a stabilizing link between the barrier and perijunctional
actomyosin.
INTRODUCTION
Tight junctions form size- and charge-selective barriers to
the paracellular movement of solutes and ions across epi-
thelia (Powell, 1981; Madara, 1998). More than 40 different
cytoplasmic and transmembrane proteins are located at the
junction (Gonzalez-Mariscal et al., 2003; Schneeberger and
Lynch, 2004; Guillemot et al., 2008) yet there is limited
knowledge of how most contribute to the junction’s selective
sealing properties. The cytoplasmic protein ZO-1 was the
first tight junction protein to be identified (Stevenson et al.,
1986). It is a member of the MAGUK family of membrane-
associated scaffolding proteins (Funke et al., 2005) and con-
tains protein-binding domains for all the major transmem-
brane barrier proteins: claudins (Furuse et al., 1998; Itoh et al.,
1999), occludin (Furuse et al., 1994; Fanning et al., 1998),
tricellulin (Ikenouchi et al., 2005; Riazuddin et al., 2006),
JAM-A (Martin-Padura et al., 1998; Ebnet et al., 2000), and
several components of the perijunctional network of actin
and myosin (Tsukita et al., 2001; Hartsock and Nelson, 2008;
Yamazaki et al., 2008). Although ZO-1 gene deletions are
embryonic lethal in mice (Katsuno et al., 2008), the depletion
of ZO-1 in cultured epithelial cell models (Umeda et al., 2004;
McNeil et al., 2006) results in only a delay in barrier forma-
tion. Once tight junctions are formed in the ZO-1–depleted
cells, TER and flux for large (40 kDa) solutes are reported to
be essentially normal (Umeda et al., 2004). There is no direct
evidence to date suggesting that ZO-1 normally limits solute
permeation in an intact tight junction, despite a widely held
view that ZO-1 is a functionally critical tight junction com-
ponent.
Permeation of solutes through the intact tight junction can
be described by two components. The first is transport
through a system of 4-Å radius charge-selective claudin-
based pores, most often quantified by transepithelial elec-
trical resistance (TER; Powell, 1981); this is a nearly in-
stantaneous electrical assessment (typically 0.25-several
seconds) of ionic permeation through the tight junction. TER
is determined by the pattern of claudins in the epithelium
and their different electrostatic permeability characteristics
(Van Itallie and Anderson, 2006; Angelow et al., 2008). The
second component is a lower capacity pathway for solutes
larger than 4 Å in radius, which shows no selectivity for
ionic charge or size (Adson et al., 1994; Knipp et al., 1997).
Although the structural and mechanistic basis of this path-
way is unknown, one speculation is that it represents dy-
namic breaks and resealing in the junction’s cell–cell con-
tacts (Sasaki et al., 2003; Watson et al., 2005). This pathway
must be measured over longer time periods (typically
60–180 min) by flux of tracers that are larger than the pores,
often mannitol (4.2 Å radius; Schultz and Solomon, 1961) or
much larger fluorescent dextrans. A more continuous assess-
ment of permeability as a function of molecular radius can
be made by determining the permeability for a graded series
of noncharged polyethylene glycol oligomers (Watson et al.,
2001; Van Itallie et al., 2008); this methods allows simulta-
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neous quantification of flux through both the small claudin-
based pores and the low-capacity break pathway.
Although measurement of TER and solute flux are often
combined to describe a monolayer’s “permeability,” they rep-
resent different structural and functional characteristics of the
barrier, as is evidenced by observations that they do not nec-
essarily change in parallel (Balda et al., 1996; McCarthy et
al., 2000). The distinction between these two pathways is
important. The first is the physiologically relevant path-
way for transepithelial salt and water transport; its charge
selectivity, electrical resistance, and level of permeability
influences overall transepithelial transport (Diamond,
1977; Powell, 1981). The second pathway is enhanced by
pathological insults allowing transepithelial movement of
larger material such as antigens, proinflammatory bacte-
rial fragments or even bacteria and viruses (Clayburgh et
al., 2004; Mankertz and Schulzke, 2007). Thus, elucidation
of the molecular basis for this second pathway is critical to
our understanding of barrier disruption in pathological
situations.
There is considerable evidence that perijunctional actin
and the activity of myosin influence the second, suprapore,
pathway (Turner et al., 1997; Madara, 1998). For example,
flux is enhanced by disruption of F-actin (Bentzel et al., 1980;
Shen and Turner, 2005) or by activation of nonmuscle my-
osin 2 ATPase activity by myosin light-chain kinase (MLCK;
Zolotarevsky et al., 2002; Wang et al., 2005; Su et al., 2009)
downstream in the RhoA and Rho kinase (ROCK) signaling
pathways (Samarin and Nusrat, 2009). Significantly, ZO-1
binds to several myosin-associated proteins, including cin-
gulin (Cordenonsi et al., 1999) and Shroom2 (Etournay et al.,
2007), to multiple proteins that regulate actin dynamics
(Hartsock and Nelson, 2008) and to F-actin itself (Fanning et
al., 2002). Furthermore, ZO-1 is one of the few cytoplasmic
proteins known to bind directly to the transmembrane bar-
rier proteins of the tight junction, a short list that also in-
cludes the multi-PDZ protein MUPP1 (Hamazaki et al., 2002)
and the homologues ZO-2 (Fanning et al., 1998; Itoh et al.,
1999) and ZO-3 (Haskins et al., 1998; Itoh et al., 1999). Thus,
ZO-1 is an ideal candidate to provide a crucial link between
perijunctional actomyosin activity and the transmembrane
barrier proteins.
To address the role of ZO-1 in the intact tight junction we
generated stable Madin-Darby canine kidney (MDCK) cell
lines expressing ZO-1 short hairpin RNAs (shRNAs) and
assessed the tight junction barrier with a variety of assays
and after cytoskeletal provocations. ZO-1 depletion resulted
in an increase in the permeability specifically for solutes
larger than 4 Å and in morphological changes and reor-
ganization of actin. The barrier in knockdown cells also
showed responses different from those in wild-type cells to
manipulations affecting actin polymerization and myosin
activity. We conclude that ZO-1 is a critical link that stabi-
lizes the barrier for larger solutes and couples it to the
myosin–actin cytoskeleton.
MATERIALS AND METHODS
Cell Culture, Immunoblots, Immunofluorescence
Tet-off MDCK II cells (Clontech, Mountain View, CA) were cultured under
standard conditions in DMEM (4.5 g/l glucose), 10% fetal bovine serum, and
pen-strep. To produce ZO-1 and ZO-2 knockdown cell lines, tet-off MDCK II
cells were cotransfected with pSVZeo (Invitrogen, Carlsbad, CA) and a mix-
ture of three different ZO-1 or -2 shRNAs (Supplemental Figure S1) cloned
into the BglII/HindIII sites of the pSuper vector (Oligoengine, Seattle, WA).
All transfections were performed with Amaxa nucleofector technology
(Lonza, Cologne, Germany) using the manufacturer’s recommended condi-
tions for MDCK II cells. Stable cell lines were selected in 1 mg/ml zeocin
(InvivoGen, San Diego, CA). Antibiotic-resistant clonal cell lines were
screened by immunoblotting and immunofluorescence; three separate clones
were selected from each of two separate transfections. ZO-1 rescue constructs
(see Figure 4A) were cloned into pTRE vector (BD Biosciences, San Jose, CA)
and cotransfected into knockdown cells with pTK hyg (BD Biosciences) or
pBlast49 (InvivoGen). Antibiotic-resistant clonal cell lines were selected with
200 g/ml hygromycin (Roche, Nutley, NJ) or 10 g/ml blastocidin (Invivo-
Gen) and screened as above; at least three independent clones inducibly
expressing each of the three rescue constructs were used in further analyses.
For all experiments unless otherwise indicated cells were cultured for 7–10
d on Transwell permeable supports (0.4-m polyester membrane, 12-mm
inserts, Corning, Corning, NY). Immunoblotting and immunofluorescence
microscopy of the cultured cells were performed as described previously
(Colegio et al., 2002; Van Itallie et al., 2003). Unless otherwise noted, all
antibodies were from Invitrogen, Carlsbad, CA). The anti-ZO-1 rat monoclo-
nal was a gift from Dr. Bruce Stevenson (Scripps, La Jolla, CA; Stevenson et al.,
1986); the guinea pig anti-human occludin antibody used in Figure 3E was
from Hycult Biotechnology (Uden, Netherlands); the myosin 2B (myo2B)
antibody was purchased from Covance (Emeryville, CA); the cingulin anti-
body was a gift from Dr. Sandra Citi (University of Geneva, Switzerland). The
anti-human guinea pig polyclonal antibody used in this experiment also
recognized the central cilium; this is not seen with other occludin antibodies.
Filamentous actin was visualized using rhodamine-phalloidin (Molecular
Probes, Invitrogen, Eugene, OR). Affinity-purified Cy-2–, -3–, and -5–labeled
secondary antibodies for immunofluorescence were from Jackson ImmunoRe-
search (West Grove, PA), and IR680/700 and 800 labeled secondary antibod-
ies for immunoblotting were from Invitrogen and Rockland Immunochemi-
cals (Gilbertsville, PA).
Wide-field images were acquired on a Nikon E800 microscope (Melville,
NY) using 60 or 100 Plan Apo lenses and an Orca ER cooled CCD camera
controlled with the Metamorph Imaging software package (ver. 6.0; Universal
Imaging, West Chester, PA). Filter sets and dye combinations have been
previously described (Fanning et al., 2002). Confocal images were acquired on
a Zeiss LSM510 Meta using a 63 Plan Apo lens (Thornwood, NY). Confocal
Stacks and image projections were generated with Zeiss LSM Image Browser
(ver. 3.2). All confocal images are maximum density projections of three
image planes representing 1.05-m final depth. Contrast adjustment and
montages were generated using Adobe Photoshop (ver. 7.0; San Jose, CA).
Barrier Assays: Polyethylene Glycol, FITC-Dextran and
Mannitol Permeability, Transepithelial Electrical
Resistance, and Dilution Potentials
Polyethylene glycol (PEG) profiling to determine the size dependence of
permeability has been described recently (Van Itallie et al., 2008); to correct the
Papp of the size-dependent first phase, the second phase is extended after
linear regression and subtracted from the first phase (Van Itallie et al., 2008).
Determination of [3H]mannitol flux and dilution potentials were performed
as described previously (Van Itallie et al., 2001). Dilution potential experi-
ments were performed on cells plated on removable permeable supports
(Snapwell, Corning). Transepithelial electrical resistance was determined us-
ing plate electrodes placed on either side of the monolayer attached to an
EVOM (WPI, Sarasota, FL). FITC-dextran permeability was measured after
preincubation of monolayers in Hanks’ buffered salt solution (HBSS) contain-
ing CaCl2 and MgSO4; fluorescein-conjugated dextran (FD), 3 or 10 kDa
(Molecular Probes, Invitrogen), was added to the apical compartment at a
concentration of 1 mg/ml, and samples were removed from the basolateral
compartment at the indicated times. Dextran flux was identical in the apical-
to-basal and basal-to-apical directions over the time course of the experiment,
suggesting negligible contribution from transcytosis. Fluorescent-dextran
concentrations were quantified using a Typhoon 8600 and Image Quant
software (Amersham Pharmacia Biotech, Piscataway, NJ); experimental val-
ues were determined by extrapolation from a standard curve of known
fluorescent-dextran concentrations using linear regression (GraphPad Prism,
San Diego, CA). Apparent Permeabilities (Papp) were defined as (dQ/dt)/
ACo (Van Itallie et al., 2008). Statistical analysis (ANOVA, Dunett’s and t tests)
were performed using GraphPad software.
Pharmacologic Reagents
Cytochalasin D and InSolution Y-27632 were purchased from Calbiochem
(EMD Biosciences, San Diego, CA); S-()-blebbistatin was purchased from
Toronto Research Chemicals (North York, ON, Canada).
RESULTS
ZO-1 Knockdown in MDCK Monolayers Changes Cell
Contact Morphology and the Organization of Apical
Actin
Previous studies demonstrated the requirement for ZO-1 for
normal assembly kinetics of the tight junction (Umeda et al.,
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2004; McNeil et al., 2006). We used a similar knockdown
approach in MDCK cells, but asked whether depletion of
ZO-1 had an effect on barrier properties at steady state, i.e.,
after the junction had sealed. We stably expressed specific
shRNAs in the pSuper vector and isolated stable clonal cell
lines on the basis of zeocin resistance. Of these, six clones
(e.g., see Figure 1A, KD clones 1–3) showed significant re-
duction of ZO-1 protein levels ranging from 95 to 97% when
compared with controls and were chosen for further analy-
sis. The levels of other tight and adherens junction proteins
were not consistently affected by knockdown of ZO-1, in-
cluding ZO-2, occludin, and claudin-2 (Figure 1A). There
were also no consistent differences between control and
knockdown cells in the expression levels of claudins 1, 3, 4,
7, actin, tricellulin, cadherin, or -catenin (not shown).
Immunofluorescence microscopic analysis of ZO-1 knock-
down cells revealed a striking alteration in cell contact mor-
phology compared with controls. Confluent MDCK II cells
typically have convoluted cell–cell contacts at the apical
junctional region, as revealed by localization of any of the
tight junction proteins, such as ZO-1 or claudin-2 (Figure
1B). Actin is distributed uniformly throughout the cell cortex
of MDCK cells and notably is concentrated in basal stress
fibers (not shown). In addition, a thin band of cortical actin
staining colocalizes with ZO-1 and other cell junction pro-
teins at the apical junctional complex (Figure 1B). When
ZO-1 levels are reduced, there is a conversion from tortuous
into linear contacts as revealed by the immunolocalization of
claudin-2 and the residual ZO-1 (Figure 1B). More dramat-
ically, actin staining is now enriched at both the apical
junctional complex and in intense apical dots (Figure 1B). All
knockdown cell lines showed this altered junctional mor-
phology and actin reorganization. A conversion from con-
voluted to straight cell contacts was previously reported
after overexpression of Shroom2, a ZO-1–binding protein
that also binds actin and myosin VIIIa (Hildebrand, 2005).
Depletion of ZO-1 Destabilizes the Barrier for Large
Solutes But Does Not Disrupt the Claudin-based Pores
Solute permeation through the tight junction can be de-
scribed by two pathways; solutes and ions smaller than
4 Å radius pass through claudin-based pores; although the
physical pathway for larger solutes is unclear, it may repre-
sent transient breaks in the barrier (Sasaki et al., 2003;
Watson et al., 2005). To determine the role of ZO-1 in regu-
lating these two components of paracellular permeability,
we profiled the apparent permeability (Papp) of a graded
series of PEG oligomers in control and ZO-1 knockdown
monolayers. This method allows us to determine simulta-
neous changes in Papp at different molecular radii (Van
Itallie et al., 2008). Comparison of MDCK parental cell lines
to four separate knockdown clones demonstrated no differ-
ence in Papp for PEG oligomers below 4 Å but about a
twofold increase in Papp for PEG oligomers larger than 4 Å
(Figure 2A). This twofold increase in Papp was confirmed by
two other flux markers (Figure 2B); [3H]mannitol, which has
Figure 1. Immunoblot and immunofluorescent charac-
terization of ZO-1 knockdown (KD) MDCK monolayers.
(A) Immunoblots of ZO-1 and -2, occludin (ocln), and
claudin-2 (cldn2) in control MDCK monolayers and in
three independent stable KD clones (1, 2, and 3). KD lines
show a 95–97% reduction in ZO-1 levels as quantified by
densitometry. KD does not alter the levels of the other
proteins. (B) Coimmunolocalization of ZO-1 and clau-
din-2, and ZO-1 and actin in MDCK control monolayers
(top panels) show normally convoluted apical junctional
staining. Similar colocalization in KD cells (bottom panels)
demonstrates straighter cell junctions and striking redis-
tribution of actin localization. Bar, 10 m.
Figure 2. ZO-1 KD cell lines show increased permeability for
solutes larger than 3.7Å. (A) Papp as a function of PEG radius in
MDCK II cells reveals no significant change in flux for small PEGs
(3.2- and 3.5-Å radius) but a significant increase in flux for all PEGs
3.7–7.0 Å (n  4 independent KD cell lines, measured on triplicate
filters, p  0.01). (B) Significant (p  0.01) increase in flux for larger
PEGs was verified by comparison with other methods. Papp for PEG
with 4.3-Å radius was identical to flux determined using [3H]man-
nitol (4.2-Å hydrated radius; Schultz and Solomon, 1961), whereas
there was a similar increase in Papp using 3-kDa FD, both measured
using three independent clones, on triplicate filters. (C) In spite of
increased flux there was a slight but significant increase in TER in
KD cell lines (n  6, three filters each); expression of full-length
human ZO-1 (FLZO1) in KD cell line (measure in triplicate) resulted
in TER indistinguishable from control.
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a hydrated radius of 4.2 Å (Schultz and Solomon, 1961)
similar to the hydrated radius of PEG8 (4.3 Å) and 3-kDa FD,
which has a molecular radius of 14Å (Kondoh et al., 2005).
Both tracers show the same twofold increase in permeability
in the ZO-1 knockdown cells when compared with controls,
even though the absolute value of Papp for the FD is only 3%
that of mannitol. This lower baseline flux of the 3-kDa FD is
likely a function of its lower diffusion coefficient. The in-
creased flux of larger compounds in ZO-1 knockdowns is
unlikely to represent the formation of a new size-restrictive
pore, because there is no evidence for a second inflection
point in the permeability data. Instead there is a propor-
tional increase in the flux of all solutes that are larger than
the claudin pores, at least for molecules up to 14 Å in radius.
When flux of a much larger 10-kDa FD was measured, there
was a small but not statistically significant increase in flux in
knockdown cells compared with control cells (not shown).
The lack of effect on the flux of molecules through the
claudin-based pores suggests that depletion of ZO-1 does
not change the biochemical components of this barrier; this
is consistent with the lack of effect on the levels and subcel-
lular localization of the tight junction barrier proteins. It is
further supported by the finding that ZO-1 knockdown re-
sults in a slight but significant increase in TER (Figure 2C),
which is the opposite of what would be expected if pores
were disrupted. The additional finding that there is no
change in the paracellular dilution potential (not shown) is
also consistent with the lack of change in the profile of
claudins lining the pores in the knockdown cells. The ap-
parent increase in Papp in ZO-1–depleted cells for PEGs,
which are 4 Å, Figure 2A, does not represent a real in-
crease in permeability of the pores. The smallest PEGs can
also pass through the leakier large pathway, so that subtrac-
tion of the contribution of the leak pathway from the values
for the small-pore pathway reveals that the Papp for the
smallest PEGs is identical between wild-type and knock-
down cells.
ZO-2 Depletion Does Not Replicate the Morphological
and Barrier Phenotypes of ZO-1 Depletion
ZO-2 binds to ZO-1, colocalizes at the junction, and shares
several key protein-binding domains (Roh and Margolis,
2003; Utepbergenov et al., 2006), suggesting it, like ZO-1,
might also regulate solute flux. To test this hypothesis, we
used shRNA methods to generate stable clonal MDCK cells
lines depleted of ZO-2 (Figure 3). Similar to what was re-
ported in Eph4 cell ZO-2 knockdown cells (Umeda et al.,
2006), in MDCK II cells stable ZO-2 depletion did not alter
the levels of ZO-1 or occludin (Figure 3A). Immunofluores-
cent analysis of ZO-2 knockdowns revealed that, unlike
ZO-1 knockdowns, ZO-2–depleted cells still showed the
convoluted cell–cell contact morphology characteristic of
wild-type MDCK II cells (Figure 3B). Also unlike ZO-1
knockdowns, localization of apical myo2B and actin was
comparable to that seen in wild-type MDCK cells (Figure
3C). The enlargement in the rightmost panel (Figure 3C,
right) reveals that apical myo2B staining appears mostly
continuous in both the wild-type and ZO-2 knockdown
MDCK cells, but is more punctuate in the ZO-1 knock-
downs. Analysis of paracellular solute permeability using
PEG size profiling revealed no difference in the Papp for any
PEG size either below or above the size of claudin pores
(Figure 3D); in addition, ZO-2 knockdown did not affect TER
(not shown). Thus, unlike ZO-1 the knockdown of ZO-2 had
Figure 3. Stable ZO-2 KD in MDCK II cells
changes neither cell morphology nor solute per-
meability. (A) Immunoblot analysis of MDCK
control cells and three independent stable ZO-2
KD demonstrate a large decrease in ZO-2 levels
(97%). ZO-2 KD has no effect on ZO-1 or occlu-
din levels. (B) Unlike ZO-1 KDs, ZO-2 KD cells
exhibit similar convoluted apical junctions as
seen in MDCK control cells. (C) immunofluores-
cence localization for myosin 2B (myo2B) and
actin are similar in MDCK and ZO-2 KD cells, but
altered in ZO-1 KD cell lines (see rightmost panel,
4 enlargement of myo2B staining). (D) ZO-2 KD
has no effect on Papp for any PEG sizes (three
independent clones, measured on triplicate fil-
ters), nor does it alter TER measurements (not
shown).
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no effects on morphology or barrier physiology. The appar-
ent cell size difference in Figure 3B between ZO-1 knock-
down cells and controls or ZO-2 knockdowns was not a
consistent finding.
ZO-1 or the N-Terminal Half of ZO-1 Rescues the Barrier
Defects of ZO-1 Depletion
To determine if reexpression of full-length ZO-1 can rescue
the barrier defect caused by depletion of ZO-1, we intro-
duced the ZO-1 knockdown vectors into an MDCK cell line
that had been previously engineered to express an inducible
human ZO-1 (Fanning et al., 2007). Knockdown vectors were
designed to interfere with expression of canine but not hu-
man ZO-1. The levels of endogenous canine ZO-1 in these
rescue cell lines was significantly reduced (to 5% of that
seen in the parental line), comparable to that seen in the
knockdown lines described above. Induction of the recom-
binant full-length human ZO-1 (FLZO1, diagrammed in Fig-
ure 4A) in ZO-1 knockdown cell lines restored ZO-1 to levels
that were 12–17% of those seen in the parental lines. Thus,
although expression was lower than in wild-type MDCK
cells, levels are induced at least threefold over the protein
levels in knockdown cells (Figure 4B). Immunofluorescent
analysis in ZO-1 knockdown and rescue cells demonstrated
that FLZO1 is appropriately localized to tight junctions in
induced cells (Figure 4C) in either the presence or absence of
the endogenous canine ZO-1 (Figure 4C), although there is a
small increase in cytosolic ZO-1 staining when the transgene
Figure 4. Reexpression of full-length human
ZO-1 and -1 fragments restores Papp to control
levels. (A) Diagram of rescue constructs. Top,
ZO1FL full-length human ZO-1; ABR deletes
only the direct actin-binding region (AA1183-
1663; Fanning et al., 2002), Nterm contains
amino acids 1-888. The ZO-1 KD cells were
created in the MDCK Tet-off cell line, and all
rescue constructs were inducible by removal of
doxycycline. (B) Expression of FLZO1 in
MDCK tet-off cells results in increased ZO-1
levels (135% of control); ZO-1 KD reduces en-
dogenous ZO-1 to 3–5% of control levels. In-
duction of ZO1FL in KD cells increases ZO-1
levels 3–4-fold over KD values, but only to 15%
of control levels. No treatment altered ZO-2 or
occludin (ocln) protein levels. (C) Immunoflu-
orescence localization of ZO-1 in control (unin-
duced, top left panel), MDCK II cells overex-
pressing human ZO-1 (induced, top right), KD
cells (uninduced, bottom left and KD cells in-
duced (bottom right) to express human ZO-1.
All constructs show similar tight junction local-
ization. (D) PEG profiling of KD and rescue cell
lines. MDCK cells induced (I) or not (U) to
express exogenous ZO-1 and KD cells induced
(I) to express human ZO-1 all show indistin-
guishable flux profiles. Only KD cells not in-
duced to express the full-length rescue con-
struct have consistently higher permeability
(p  0.05 compared with controls, triplicate
filters for each clone per experiment, three sep-
arate experiments). (E) ZO-1 rescue fragments
(green) are inducible and do not alter ZO-2
levels (red). Endogenous ZO-1 expression lev-
els are not affected by doxycycline induction in
either MDCK II or KD cells. When KD cells
were stably transfected with rescue constructs
as above, transgene expression was not detect-
able in the uninduced cells (U) but was clearly
induced by doxycycline removal (I). ZO-2 lev-
els were not affected by transgene induction.
(F) Immunofluorescence localization of in-
duced transgenes demonstrates localization to
apical junctional complex and colocalization
with occludin. The anti-human guinea pig
polyclonal antibody used in this experiment
also recognized the central cilium; this is not
seen with other occludin antibodies. (G) Papp of
3-kDa FD reveals significantly increased flux
(p  0.05) in all KD cells lines in the absence of
expression of recue constructs; induction of all
rescue constructs (one FLZO1 clone mea-
sured  dox, three independent clones for
ABR and Nterm measured  dox on triplicate filters) returns Papp for FD to levels indistinguishable from control values. (H) Induction of
all rescue constructs significantly decreases TER values in all KD cell lines (as above, p  0.001).
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is induced in ZO-1 knockdown cells. Notably, there is some
increase in tortuosity of the junction contacts when FLZO1 is
restored in knockdown cells.
Despite low expression levels, FLZO1 clearly rescues the
enhanced permeability seen in ZO1 knockdown cells as
revealed by PEG permeability profiling (Figure 4D). Similar
to experiments described above, in the absence of FLZO1
expression (, Figure 4D) the ZO1 knockdown lines dem-
onstrated increased flux of PEG oligomers of 4 Å and above,
whereas induction of FLZO1 in these cells restored Papp for
the larger PEGs to control levels (f, Figure 4D). There was
no significant difference in permeability for the PEG oli-
gomers 4 Å in any of the knockdown or rescue cell lines.
As expected, expression of FL ZO1 in the parental cell line
(which already expresses endogenous ZO-1) had no discern-
able effect on Papp for the small or large PEG oligomers.
To determine critical regions of ZO-1 responsible for res-
cuing the barrier defect seen in knockdown cells, we trans-
fected ZO-1 knockdown cells with tet-inducible human
ZO-1 constructs missing either the actin-binding region
(ABR, Figure 4A) or encoding only the N-terminal 888
amino acids (Nterm, Figure 4A). Immunoblot analysis dem-
onstrates that both ABR and Nterm are efficiently induced
and expressed at levels comparable to FLZO1, and neither
endogenous ZO-1 nor knockdown ZO-1 levels are affected
by the presence (U, uninduced) or absence (I, induced) of
doxycycline (the suppressing agent). Furthermore, ZO-2 lev-
els are unchanged by doxycycline treatment (Figure 4E).
Immunofluorescent analysis of induced and uninduced cells
demonstrates that both deletion constructs localize to the
apical junctional complex (Figure 4F). Expression of the
ABR causes some slight return of the convoluted tight
junction morphology seen in control cells, but without a
reliable method for quantification, the degree of this rescue
is difficult to assess. There is no apparent rescue of the
convoluted tight junction morphology with expression of
the Nterm construct.
Permeability of 3-kDa FD was significantly increased in all
of the MDCK rescue lines before induction of rescue trans-
genes (Figure 4G), although the level of increase was vari-
able in different clonal cell lines. Nevertheless, induction of
any of the transgenes (FL, ABR, or Nterm) completely
reverses the Papp increase to control levels (Figure 4G). Sim-
ilarly, all of the knockdown cell lines show increased TER
relative to MDCK II controls (Figure 4H); in each case,
induction of the rescue construct significantly reduces TER
to levels similar to MDCK controls or below. These findings
suggest that regions sufficient for physiological stabilization
of the barrier lie within the amino terminal half of ZO-1.
ZO-1–depleted Cell Lines Demonstrate Increased
Sensitivity to Both Cytochalasin D and Ca2 Removal
ZO-1 has been demonstrated to bind F-actin directly (Fanning
et al., 1998) and indirectly (reviewed in Hartsock and Nelson,
2008). The phenotype of MDCK knockdown monolayers is
consistent with the possibility that ZO-1 is required to main-
tain the normal perijunctional actin cytoskeleton and stabi-
lize the barrier. Because disruption of the actin cytoskeleton
with cytochalasin D is known to disrupt tight junction bar-
rier function (Bentzel et al., 1980; Stevenson and Begg, 1994;
Shen and Turner, 2005), we asked whether ZO-1 knock-
downs might demonstrate increased sensitivity to cytocha-
lasin D. After culture for 7–10 d on filters, control MDCK II
cells are remarkably resistant to cytochalasin D treatment as
measured by TER (Figure 5A). In contrast, cytochalasin D
treatment of ZO-1 knockdown cells results in a significant
time-dependent drop in TER. These results are consistent
with a role for ZO-1 in stabilizing normal actin organization
required to maintain the barrier.
We also tested the role of ZO-1 in stabilizing the barrier
after Ca2	 removal. Transferring confluent MDCK II cell
monolayers into low Ca2	 media (5 M) results in a de-
crease in TER that reaches a stable level at 60 min (Figure
5B). Ca2	 removal from ZO-1 knockdown cells results in a
significantly faster decrease in TER, reaching a new plateau
level at 15 min. As previously reported by others, we also
observed a delay in the reformation of tight junctions after
Ca2	 replacement in the knockdown cells relative to control
cells (not shown). Although it is not known precisely how Ca2	
removal leads to barrier loss, our results are again consistent
with a role for ZO-1 in tight junction stabilization.
The Barrier Is Functionally Uncoupled from Myosin in
ZO-1–depleted Monolayers
Many studies have demonstrated a role for myosin in the
regulation of paracellular permeability (reviewed in Turner,
2006; Ivanov, 2008), but the functional links between the
tight junction and actomyosin have not been established. To
determine whether ZO-1 is such a link, we asked whether
depletion of ZO-1 changes the sensitivity of the barrier to
agents that alter myosin ATPase activity, namely the ROCK
inhibitor Y27632 and myosin inhibitor blebbistatin.
ROCK is thought to activate nonmuscle myosin 2 ATPase
through both direct phosphorylation of the regulatory light
chain and by inhibition of myosin light chain (MLC) dephos-
phorylation (Amano et al., 1996; Kimura et al., 1996; Nakai et
al., 1997). There is no single model for how myosin controls
Figure 5. ZO-1 KDs are more sensitive to cytochalasin D treatment
and Ca2	 removal than are control MDCK cells. (A) MDCK and KD
cells cultured for 7 d on Transwell filters were preincubated in HBSS
containing Ca2	 and Mg2	 for 20 min and TER was measured.
Monolayers were then changed into fresh media containing either
DMSO or 10 g/ml cytochalasin D in DMSO. TER was measured on
triplicate filters at the indicated times; * p  0.05 or less, similar
results were obtained with a second KD cell line. (B) MDCK and KD
cells were cultured as above; TER was measured and cells were
washed four times with Ca2	-free SMEM and then incubated in
SMEM supplemented with 10% dialyzed (against EGTA) fetal bo-
vine serum and 5 M CaCl2. TER was measured at the indicated
times, measurements made on triplicate filters; * p  0.05 or less;
similar results were obtained with a second KD cell line.
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the barrier. For example, administration of the ROCK inhib-
itor Y27632 increases basal TER in confluent MDCK cells
(Fujita et al., 2000) yet has the opposite effect in T84 cells
(Walsh et al., 2001). These differing responses may represent
different levels of myosin activation (Ivanov, 2008) or the
activity of other downstream targets of ROCK (Riento and
Ridley, 2003). With this caveat we tested whether depletion
of ZO-1 altered coupling between myosin activity and the
barrier. As previously reported, Y27632 increased TER in
our wild-type MDCK II cells in a dose-dependent manner
(Figure 6A). This increase was similar at 2, 6, and 24 h; the
dose dependence at 24 h is shown in Figure 6A. In contrast,
ZO-1–depleted monolayers were strikingly insensitive to
Y27632 at any dose or time.
Solute permeability showed a similar insensitivity to
Y27632. In control MDCK cells 24 h of treatment with
Y27632 increased permeability for both 3-kDa FD (Figure
6B) and mannitol (not shown). In contrast, ZO-1 knockdown
cells, which have higher basal dextran permeability, failed to
show further permeability increases with Y27632 adminis-
tration. The different sensitivity of these cells to Y27362
correlates with differential response in myosin immunolo-
calization in control and knockdown cells after Y27632 treat-
ment. myo2B immunofluorescence at apical junctional con-
tacts follows the convoluted cell contacts characteristic of
wild-type MDCK cells (Figure 6C), whereas in the ZO-1–
depleted cells myo2B follows the straighter cell borders that
characterize the knockdowns, with a more punctuate, less
continuous distribution (see Figure 3C, 4 magnified im-
ages). Treatment of wild-type cells with the ROCK inhibitors
decreases the membrane tortuosity of wild-type cells and
slightly increases the intensity of myo2B staining at apical
cell borders. Administration of the ROCK inhibitor to
ZO-1–depleted cells does not increase the intensity of myo-
sin 2B at apical cell contacts, but dramatically increases the
amount of myo2B concentrated in scattered apical spots.
Blebbistatin, unlike Y27632, is a direct inhibitor of myosin
2 activity; its administration to confluent MDCK II cell
monolayers results in a dose-dependent increase in TER,
although this increase is less pronounced than that seen after
ROCK inhibition (Figure 7A). However, unlike the effect of
the ROCK inhibitor on knockdown cells blebbistatin treat-
ment causes a significant dose-dependent decrease in TER in
the ZO-1–depleted cells (Figure 7A). Blebbistatin adminis-
tration has no effect on permeability in the control cells,
whereas in knockdown cells it further elevated 3-kDa FD
flux (Figure 7B). In addition, blebbistatin administration re-
sulted in a more pronounced relocalization of myo2B in
knockdown cells when compared with control cells (Figure
7C). The reasons for the changes in morphology are unclear,
but they are consistent with an influence of ZO-1 on myosin
organization, perhaps through its interaction with actin. One
important caveat is that only a fraction of the cellular actin
and myosin are localized to the tight junction, and the ROCK
inhibitor and blebbistatin have multiple cellular actions.
DISCUSSION
In the current study we demonstrate that ZO-1 depletion in
MDCK cells results in a size-selective increase in permeabil-
ity for solutes that are larger than the claudin-based pores. In
addition, ZO-1 depletion results in uncoupling of the normal
barrier response to inhibition of myosin activity. The barrier
defect does not involve a disruption of the small claudin-
based pores as measured by the Papp of PEGs 4 Å or by
TER. In fact, TER, a measure of instantaneous ionic perme-
ability, is slightly but significantly increased in knockdown
cells relative to controls. The increased permeability for
Figure 6. MDCK II control and ZO-1 KD cells
show differential sensitivity to the Rho kinase
(ROCK) inhibitor Y27632. (A) Cells were cul-
tured on filters for 7 d and then changed into
media containing vehicle or the indicated doses
of Y27632. TER was measured at 0, 2, 6, and
20 h (shown); there was little difference in ef-
fects on TER at any time point. MDCK control
but not KD cells demonstrated a dose-depen-
dent (triplicate filters, p  0.001) increase in
TER. (B) Cells treated with 30 M Y27632 for
20 h as above were used for flux measurement;
there was a significant increase in Papp for
3-kDa FD after treatment with ROCK inhibitor
but no further elevation in flux in KDs (tripli-
cate filters, * p  0.05 compared with vehicle,
** p  0.001 compared with vehicle-treated
MDCK cells, and # no significant difference
with vehicle-treated KD cells.) (C) Immunoflu-
orescence analysis of vehicle and Y27632-
treated MDCK and KD cells lines. Ethanol-
fixed MDCK monolayers cultured on filters
and treated with 30 M Y27632 for 20 h as
above were stained for ZO-1 and Myo2B;
Y27632 treatment increased apical junctional
immunolocalization of Myo2B in control cells
but not in KDs, but increased apical spots in
KD cells. Bar, 5 m.
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larger solutes is rescued by expression of both full-length
ZO-1 and a truncated construct containing amino-terminal
domains that, among other things, binds to all of the know
tight junction transmembrane proteins (Figure 8). ZO-1 de-
pletion also results in enhanced sensitivity to Ca2	-deple-
tion and actin disruption with cytochalasin D. Taken to-
gether this is the first direct evidence that ZO-1 normally
serves to stabilize the barrier and functionally link it to the
actin–myosin cytoskeleton.
Although ZO-1 is a universal component of tight junctions
and interacts with multiple other tight junction proteins, two
recent studies (Umeda et al., 2004; McNeil et al., 2006) re-
ported limited physiological consequences after ZO-1
knockout or knockdown in epithelial cells. In contrast, in the
current study we demonstrate a requirement for ZO-1 in
normal barrier function in MDCK cells and show that
ZO-1–depleted MDCK cells have an altered morphology
characterized by a loss of tortuosity at the apical junction
contacts and changes in apical actin localization. The reasons
for the differences between previously published studies
and our findings are likely a function of both cell type and
methodology. Umeda et al. (2004) used homologous recom-
bination to knockout ZO-1 expression in Eph4 cells and
reported no change in flux for 40-kDa FD; we report a
consistent increase in flux for a smaller (3 kDa) FD, but like
Umeda et al. have also found that flux of larger 10-kDa FD
was not significantly altered. Modest permeability changes
(in our case up to twofold) are more difficult to detect as the
tracer size increases, except cases where the barrier is cata-
strophically opened, for example, by Ca2	 depletion. The
lack of effect on cell morphology may be related to cell type,
because Eph4 cells normally lack the convoluted tight junc-
tion staining pattern that characterizes MDCK II cells.
Macara and coworkers (McNeil et al., 2006), on the other
hand, did not measure flux in their ZO-1 knockdown cell
lines; that they did not note a change in morphology is likely
to be a function of the fact that they used transient transfec-
tion to deplete ZO-1 rather than generating stable cell lines
as we have done. A third group (Aijaz et al., 2007) has also
generated stable MDCK ZO-1 knockdown cell lines. In con-
trast to our finding, they did not find an effect on paracel-
lular flux. However, this group reported a decrease in ZO-1
levels only to 25% of control levels, compared with 2–5%
remaining in our cell lines. We suspect the residual level of
ZO-1 in their cells is the reason for their failure to see change
in flux, because this level of ZO-1 expression in our ”res-
cued“ cell lines is sufficient to return flux to normal levels.
Figure 7. MDCK II control and ZO-1 KD cells
show differential sensitivity to the myosin AT-
Pase inhibitor blebbistatin. (A) Cells cultured
on filters for 7 d were washed once and prein-
cubated for 20 min in HBSS containing Ca2	
and Mg2	. Filters were then changed into fresh
HBSS with vehicle or blebbistatin at the indi-
cated doses. TER was measured after 2 h of
blebbistatin treatment. MDCK control demon-
strated a dose-dependent (* p  0.01) increase
in TER; KD cells demonstrate a dose-depen-
dent (# p  0.05) decrease in TER (triplicate
filters). (B) Cells treated with 50 M blebbista-
tin or vehicle were used for determination of
FD flux; there was no change in MDCK control
cells with blebbistatin, but blebbistatin treatment
resulted in a further significant elevation of Papp
for 3-kDa FD (* p  0.05 compared with controls,
** p  0.001 compared with vehicle-treated KD
cells, triplicate filters). (C) Immunofluorescence
analysis of vehicle and blebbistatin-treated
MDCK and KD cells lines. Ethanol-fixed MDCK
monolayers cultured on filters and treated with
vehicle 50 M blebbistatin for 2 h as above were
stained for ZO-1 and myo2B; blebbistatin treat-
ment resulted in greater disorganization of
myo2B staining in KD cells than in control cells.
Bar, 5 m.
Figure 8. Diagram of reported ZO-1–binding proteins
and their binding sites. Original references are cited in
Fanning and Anderson (2009). Many ZO-1–binding
proteins also bind actin including AF-6, cingulin, ZO-2
and -3, -catenin, Shroom 2, Protein 4.1, and cortactin.
These in turn bind many others that regulate actin dy-
namics.
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In spite of many studies which have reported changes in
ZO-1 localization in association with alterations in paracel-
lular permeability (Nusrat et al., 2000; Wang et al., 2005), the
finding that ZO-1 depletion results in increased flux in the
size-independent pathway is the first demonstration of a
clear physiological role for this much studied protein. The
observed increase in flux is modest, but it occurs in a back-
ground of some residual ZO-1 and minor or no changes in
the distribution and levels of most other tight junction pro-
teins. The increased flux is not associated with a decrease in
TER or with a change in dilution potential; these outcomes
are consistent with the immunolocalization and immunoblot
findings that the tight junction transmembrane proteins such
as claudins, occludin, and tricellulin are unchanged. Along
with the change in flux, the observed alteration in actin
localization in the knockdown cells provides clear evidence
that ZO-1 is a crucial scaffolding protein, linking a physio-
logically relevant actin pool to the tight junction barrier.
Evidence for a similar role for ZO-2 is lacking, because in
our hands, ZO-2 knockdown had no observable physiolog-
ical effect. This result is different from that reported else-
where (Hernandez et al., 2007), but could be due to the fact
that Hernandez and coworkers tested transiently transfected
cells, whereas we analyzed flux in stable knockdowns.
Increased flux for solutes which are larger than the clau-
din pores in the absence of decreased TER implies that the
long-term dynamic characteristics of the barrier are altered
by ZO-1 depletion without a compromise in the instanta-
neous electrical barrier. The tight junction is arranged as a
series of continuous claudin-based cell–cell contacts. Multi-
ple barriers presumably provide a fail-safe in case individual
contacts transiently break. We speculate that the selective
effect of ZO-1 depletion could result from more frequent
transient breaks in the contacts but without the simulta-
neous loss of all of the contacts in series. This would increase
permeability for solutes measured over long times but not
affect a fast assessment of the barrier with TER. Future
studies will test whether ZO-1–depleted junctions are more
dynamic.
Previous studies have demonstrated that a ring of fila-
mentous actin normally encircles the apical junctional
complex and have indicated that contraction of the ring is
associated with changes in cell shape and tight junction
permeability (Madara, 1987). Additionally, ultrastructural
studies have detected direct contact between actin filaments
and the tight junction, although the functional significance
of these contacts is unknown (Hirokawa et al., 1983; Madara,
1987). Our studies indicate that F-actin localization is signif-
icantly altered in the ZO-1 knockdown cells, with an in-
crease in actin staining at apical junctional complex and into
scattered apical dots. These observations suggest that ZO-1
has very specific effects on actin dynamics at the apical
junctional complex, perhaps by localizing the activity of
cytoskeletal proteins [such as  actinin; Chen et al., 2006), 
catenin (Itoh et al., 1997), or shroom2 (Etournay et al., 2007)]
or signaling pathways [such as the RhoGEF TUBA (Otani et
al., 2006) and G12 (Meyer et al., 2002)] that regulate actin
dynamics.
How these changes in actin dynamics or cortical F-actin
architecture affect permeability is a matter of speculation.
One possibility is that there is a specific cortical actin net-
work that is associated with the barrier and that the assem-
bly or plasticity of this network is organized by ZO-1 (via
contacts with cytoskeletal proteins outlined in Figure 8). In
the absence of ZO-1, the network does not maintain a nor-
mal barrier. It seems unlikely that ZO-1 acts as a direct
transducer between the physical force generated by actomy-
osin activity and components of the barrier. The C-terminus
of ZO-1 binds directly to F-actin (outlined in Figure 8);
however, because the increased flux is rescued by the Nterm
construct, which lacks the direct actin-binding site, direct
interactions between ZO-1 and F-actin do not appear essen-
tial for barrier stabilization. Instead, our data suggest that
indirect contacts via other actin-binding and/or -signaling
proteins that bind to the Nterm construct are sufficient.
Whatever the mechanism, our observations suggest that
one critical factor is the ability of ZO-1 to link the activity of
myosin 2 to the state of the barrier. Perhaps surprisingly, the
localization of myosin within the apical junctional complex
is only slightly altered in ZO-1 knockdown cells. There is a
tendency for it to become less continuous and more punc-
tuate in staining pattern. This pattern, most evident in Fig-
ure 7C, is again consistent with loss of normal interactions.
Many studies (Nusrat et al., 1995; Jou et al., 1998; Walsh et al.,
2001; Benais-Pont et al., 2003; Shen et al., 2006) have im-
plicated myosin activation in changes in paracellular flux
downstream of RhoA and MLCK. Despite the subtle changes
in myosin 2B localization, there is a clear difference between
control and ZO-1 knockdown cells in their responses to
pharmacologic inhibition of ROCK or myosin 2 ATPase.
This suggests that ZO-1 does not localize myosin 2B, but
may still act as a scaffolding protein indirectly regulating
myosin activity. For example, ZO-1 knockdown decreases
cingulin localization (Umeda et al., 2004; Supplementary
Figure S3). Cingulin (and the related protein, paracingulin,
Guillemot et al., 2008) have been demonstrated to bind the
guanidine nucleotide exchange factor, GEF-H1, which inhib-
its Rho signaling (Benais-Pont et al., 2003; Aijaz et al., 2005).
Decreased tight junction cingulin might increase Rho ac-
tivation and thus myosin phosphorylation; however, as pre-
viously reported, neither cingulin knockout (Guillemot et al.,
2004) nor knockdown (Guillemot and Citi, 2006) altered
permeability. The role of paracingulin in flux regulation
has not yet been tested. Another possibility is that ZO-1
might normally act as a sink for G12, which can bind to
the SH3 domain of ZO-1 (Meyer et al., 2002; Sabath et al.,
2008; Figure 8) and that ZO-1 depletion would lead to
increased activation of Rho A through an increase in
accessible G12.
In summary, this is the first direct experimental evidence
of a role for ZO-1 in control of paracellular permeability
through coupling it to perijunctional actin and myosin.
However, providing the evidence that ZO-1 does in fact
form a link between the barrier proteins and the cortical
cytoskeleton is just a small piece of the puzzle. A cursory
inspection of Figure 8 reveals just some of the other proteins
that might be important links in this interaction. Unraveling
the most relevant of these interactions in the physiological
regulation of the tight junction will aid in understanding
how barrier integrity is maintained and what components
are likely to be involved when the barrier is pathologically
compromised.
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